614 related articles for article (PubMed ID: 22225723)
1. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cells in the immunotherapy of melanoma.
Ouyang Z; Wu H; Li L; Luo Y; Li X; Huang G
Tumour Biol; 2016 Jan; 37(1):77-85. PubMed ID: 26515336
[TBL] [Abstract][Full Text] [Related]
3. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
4. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
[TBL] [Abstract][Full Text] [Related]
5. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
6. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Oh DS; Kim H; Oh JE; Jung HE; Lee YS; Park JH; Lee HK
Oncotarget; 2017 Jul; 8(29):47440-47453. PubMed ID: 28537894
[TBL] [Abstract][Full Text] [Related]
8. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
[TBL] [Abstract][Full Text] [Related]
9. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
10. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination.
Correll A; Tuettenberg A; Becker C; Jonuleit H
Exp Dermatol; 2010 Aug; 19(8):e213-21. PubMed ID: 20500773
[TBL] [Abstract][Full Text] [Related]
11. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
13. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
[TBL] [Abstract][Full Text] [Related]
14. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
[TBL] [Abstract][Full Text] [Related]
16. Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
Li Y; Wang Z; Lin H; Wang L; Chen X; Liu Q; Zuo Q; Hu J; Wang H; Guo J; Xie L; Tang J; Li Z; Hu L; Xu L; Zhou X; Ye L; Huang Q; Xu L
Front Immunol; 2020; 11():806. PubMed ID: 32477338
[TBL] [Abstract][Full Text] [Related]
17. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
18. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract][Full Text] [Related]
19. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.
Schatton T; Scolyer RA; Thompson JF; Mihm MC
Methods Mol Biol; 2014; 1102():287-324. PubMed ID: 24258985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]